Published • loading... • Updated
A Major Step Forward for Patients with Multiple Sclerosis!
Summary by Génération-NT
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The Ocrelizumab treatment significantly slows the progression of Primary Progressive Plate Sclerosis (PPMS), including in older or advanced patients. An extensive international study, called ORATORIO-HAND, shows a 30% reduction in the risk of progression of disability and, above all, a 41% decrease in the deterioration of hand function.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
